NovoTTF: where to go from here?

Affiliations

¹ UCLA Neuro-Oncology Program and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
² Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, USA.

Editorial

Timothy F Cloughesy et al. Neuro Oncol. 2017.

. 2017 May 1;19(5):605-608.

doi: 10.1093/neuonc/nox014.

¹ UCLA Neuro-Oncology Program and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
² Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, USA.

No abstract available

References

1. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192–2202. - PubMed
1. Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016;18(8):1129–1136. - PMC - PubMed
1. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–2543. - PubMed
1. Grady D. Electrical scalp device can slow progression of deadly brain tumors. The New York Times. November 15, 2014, A26.
1. Stupp R, Idbaih A, Steinberg DM, et al. LTBK-01: prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016; 18(suppl 6):i1. - PubMed